Alliance for the Prudent Use of Antibiotics
Mission Statement
The mission of the Alliance for the Prudent Use of Antibiotics (APUA) is to strengthen global defenses against infectious disease by ensuring access to effective treatment and promoting appropriate antibiotic use to contain drug resistance. With a network of affiliated chapters in 19 countries, APUA stands as the world’s leading organization conducting research and education on antimicrobial treatment and resistance at the grassroots and global levels.
ISAC WEBINAR | “COVID-19: Around the World in 80+ Minutes”
ISAC invites you to join its free, live webinar on 25 November 2020 at noon (12.00) GMT.
This unique webinar will bring you a global view of the pandemic from those on the frontline in diverse parts of the world. It will cover aspects of epidemiology and genomics, screening, control, treatment and consequences of infection. The speakers, all leaders in their fields, have a unique perspective of how the pandemic affects their regions.
Each session will be 15 minutes and we invite you to ask questions during the sessions or you can submit them in advance. We plan to incorporate the presentations and discussion into an ISAC Academy web tutorial. Visit ISAC.world for more information.
Latest APUA / ISAC Newsletter: October 2020
We are delighted to bring you the latest newsletter from the International Society of Antimicrobial Chemotherapy (ISAC) / Alliance for the Prudent Use of Antibiotics (APUA).
This issue contains three excellent feature articles:
• Emerging threats of antibiotics in the environment: what about the pharmaceutical industry?
VГ©ronique Mondain, Florence Lieutier-Colase
• A Multidisciplinary, French-speaking course on Antimicrobial Stewardship in Africa: the MUFASA Project
Armel Poda, Abdoul-Salam OuГ©draogo, Sylvain Godreuil, Jean- Baptiste Guiard-Schmid, Xavier Lescure, Pierre Tattevin
• Bacteriophages: when history can save the future
Fatima Allaw, Jean-Francois Jabbour, Souha S. Kanj
In addition, you can also read all the latest news from both ISAC and APUA as well as a round-up of antimicrobial resistance news.
Read and download the newsletter here
Thank you very much to all contributors. If you have any feedback or ideas for future content, please email secretariat@isac.world.
The Center for Antimicrobial Resistance renamed after APUA founder Stuart Levy
The Center for Integrated Management of Antimicrobial Resistance, a collaborative effort supported by Tufts University and Tufts Medical Center, has been renamed the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance (Levy CIMAR) in tribute to APUA founder and leader, Stuart Levy.
Levy CIMAR builds on Levy’s work and takes a One Health approach—a collaborative, multidisciplinary effort to improve the health of people, animals, and the environment—to AMR research, policy recommendations, and educational programs.
A virtual event on 18 September 2020 attended by colleagues, friends and family celebrated the renaming and the life of the pioneering antibiotic-resistance researcher who passed away one year ago. For more information, read the full story on Tufts Now.
Remembering Prof. Stuart B. Levy
It has been just one year since Stuart Levy passed away, but it already seems so long ago… Since then, the world was confronted with an unprecedented sanitary crisis, which kept us all so busy that we could hardly find time to relax. Stuart left us just before a small virus would lead to one of the most dramatic revolutions in our societies. Many paradigms have been changed at a pace none of us would have expected. The economic, educational and cultural activities, work, leisure, sports, national and international exchanges, and many other pillars of our modern civilization have been jeopardized.
Looking back to the special tribute newsletter we wrote collectively, one year ago, under the flag of the Alliance for the Prudent Use of Antibiotics (APUA), as a tribute to Professor Stuart Levy’s key publications, feels like a return to our roots. Still, most of the topics covered in these pages remain contemporary and of high value. We most likely will see the end of the COVID-19 pandemic, hopefully before the second anniversary of Stuart Levy’s death, and we will then have to boost actions for better use of antibiotics worldwide, a topic sadly neglected over the last months. By that time, all the basics and principles established by Stuart Levy and others will help us to rebuild our collective actions and thrive.
Meanwhile, we hope you all keep safe so that we have the pleasure to meet again!
Pierre Tattevin
APUA Chair
New APUA Board Member
APUA is delighted to welcome new member, Jeroen Schouten, to the APUA Board.
Jeroen is an Intensive Care Physician and Senior Researcher at IQ Health Care, Radboud University, Nijmegen Medical Centre.
He is also is a member of Dutch guideline committees for community-acquired Pneumonia, Sepsis and Antibiotic Stewardship for the Dutch Working Group for Antibiotic Policies (SWAB). Additionally, Jeroen is currently Chair of European Study Group for Antimicrobial Stewardship (ESGAP) and Chair of the Antimicrobial Stewardship Program at Radboudmc and has authored numerous publications.
With his expertise in Antimicrobial Stewardship, Jeroen will be a great addition to the team.https://apua.org/who-we-are
02 September 2020
New APUA Article: August 2020
Advocacy for Increased International Efforts for Antimicrobial Stewardship Actions in Low-and Middle-Income Countries on Behalf of Alliance for the Prudent Use of Antimicrobials (APUA), Under the Auspices of the International Society of Antimicrobial Chemotherapy (ISAC)
Pierre Tattevin, Gabriel Levy Hara, Adnene Toumi, Mushira Enani, Geoffrey Coombs, Andreas Voss, Heiman Wertheim, Armel Poda, Ziad Daoud, Ramanan Laxminarayan, Dilip Nathwani, and Ian Gould on behalf of Alliance for the Prudent Use of Antimicrobials (APUA) under the auspices of the International Society of Antimicrobial Chemotherapy (ISAC)
Front. Med., 25 August 2020 | https://doi.org/10.3389/fmed.2020.00503п»ї
Latest APUA / ISAC Newsletter: June 2020
We are pleased to bring you the latest newsletter from the Alliance for the Prudent Use of Antibiotics (APUA) / International Society of Antimicrobial Chemotherapy (ISAC).
This issue contains two excellent feature articles:
• Creating a collaborative approach to antimicrobial stewardship education across the Gulf, Middle East, and North Africa (MENA): A case study from the British Society for Antimicrobial Chemotherapy (BSAC)
Dilip Nathwani, Tracey Guise, Debbie Cockayne
• An update on e-Bug progress in France
Pia Touboul,Virginie Lacroix Hugues, Brigitte Dunais
In addition, there is a special feature section on COVID-19 in which our international Executive Committee members / APUA Board & Chapters provide accounts of the current situation in their regions.
We appreciate that everyone is exceedingly busy dealing with COVID-19 at this time so thank you to our members for their contributions:
• Andreas Voss, the Netherlands • Mushira Enani, Saudi Arabia • Souha Kanj, Lebanon • Sam Kariuki, Kenya • Peg Riley, USA
• Minggui Wang, China • Matthew Dryden, UK • Sade Ogunsola, Nigeria • Ray Saginur, Canada • Heiman Wertheim, the Netherlands
• Kumud Kafle, Nepal • Pierre Tattevin, France • Fiona MacKenzie, UK • Abdul Ghafur, India
Click here to read / download all the articles.
If you have any feedback or ideas for future content, please email secretariat@isac.world.
APUA Newsletter: Winter 2020
We are pleased to bring you the latest newsletter from the Alliance for the Prudent Use of Antibiotics (APUA). This issue contains three feature articles:
International Centre for Antimicrobial Resistance Solutions
Robert Skov, Ghada Zoubiane and KГҐre MГёlbak
The key role of non-profit, non-governmental organisations in the fight against antibiotic resistance: the example of WAAAR
Jean Carlet and Garance Upham
From bad to worse: emergence of extensively drug resistance Gram negative bacilli among immunocompromised Nigerians
Ibrahim Yusuf
To read the articles, along with the latest APUA and antimicrobial news, please click here.
"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment. Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."
Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine
From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)
